Patents Examined by Dong Jiang
-
Patent number: 11649280Abstract: The present invention relates to IL-34 antibodies, compositions comprising the same, and methods of using the antibodies and or compositions thereof for treating immune-mediated diseases such as neurodegenerative diseases, for example Alzheimer's Disease or a tauopathy disease.Type: GrantFiled: April 23, 2021Date of Patent: May 16, 2023Assignee: Eli Lilly and CompanyInventors: Marcio Chedid, Victor H. Obungu, Andrew Dixon Skora, Ming Ye
-
Patent number: 11541103Abstract: Provided herein are IL-21 muteins and fusion proteins comprising the same for use in methods of treating a disease. Related conjugates, nucleic acids, vectors, host cells, pharmaceutical compositions and kits are also provided herein. Methods of making the IL-21 muteins and fusion proteins comprising the same, as well as methods of treating a subject in need thereof, are provided by the present disclosure. Further provided are PD-1 antigen-binding proteins.Type: GrantFiled: August 3, 2018Date of Patent: January 3, 2023Assignee: Amgen Inc.Inventors: Khaled M. K. Z. Ali, Neeraj Jagdish Agrawal, Gunasekaran Kannan, Ian Foltz, Zhulun Wang, Darren Bates, Marissa Mock, Shunsuke Takenaka
-
Patent number: 11534491Abstract: The disclosure relates to novel regimens for treating an inflammatory arthritis, e.g., psoriatic arthritis, which employ a therapeutically effective amount of an Interleukin-17 (IL-17) antagonist, e.g., IL-17 binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof, e.g., secukinumab) or IL-17 receptor binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof).Type: GrantFiled: March 19, 2020Date of Patent: December 27, 2022Assignee: NOVARTIS AGInventors: Shephard Mpofu, Hanno Richards, Karthinathan Thangavelu, Matthias Machacek
-
Patent number: 11534490Abstract: The disclosure relates to novel regimens for treating psoriasis, which employ a therapeutically effective amount of an IL-17 antagonist, e.g., an IL-17 binding molecule, e.g., an IL-17 antibody, such as the secukinumab antibody, or an IL-17 receptor binding molecule, e.g., an IL-17 receptor antibody.Type: GrantFiled: December 19, 2019Date of Patent: December 27, 2022Assignee: NOVARTIS AGInventors: Achim Guettner, Matthias Machacek, Charis Papavassilis, Oliver Sander
-
Patent number: 11529415Abstract: This disclosure provides IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof. In certain aspects the anti-IL-21 antibodies and fragments thereof can be hybridoma-derived murine monoclonal antibodies, and humanized versions thereof. In certain aspects the binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof provided herein inhibit, suppress, or antagonize IL-21 activity. In addition, this disclosure provides compositions and methods for diagnosing and treating diseases or disorders, e.g., inflammatory, immune-mediated, or autoimmune diseases or disorders associated with IL-21-mediated signal transduction. In a particular embodiment, the disclosure provides methods for treating or preventing Graft-versus-host disease (GVHD) using IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof.Type: GrantFiled: February 5, 2020Date of Patent: December 20, 2022Assignee: Boston Pharmaceuticals Inc.Inventors: Catherine Ettinger, Jodi Karnell, Melissa Damschroder, Partha Chowdhury, Xiaodong Xiao, Ping Tsui, Reena Varkey, Stacey Drabic, Laura Carter, Ronald Herbst, Qun Du, Brian Michael Naiman
-
Patent number: 11517611Abstract: The present invention is directed to compositions including the cytokines IL-18 and IL-22 or biologically active fragments or variants thereof. In some embodiments, the compositions further include a pharmaceutically acceptable carrier. The compositions can farther include other interleukins such as IL-1?, and IL-1? can be used as a combination therapy with either IL-18 or IL-22 or biologically active fragments or variants thereof.Type: GrantFiled: April 23, 2020Date of Patent: December 6, 2022Assignee: Georgia State University Research Foundation, Inc.Inventors: Andrew T. Gewirtz, Benyue Zhang
-
Patent number: 11505612Abstract: The present disclosure relates to AM-14 pharmaceutical formulations and therapeutic dosing regimens for the treatment of disease.Type: GrantFiled: September 8, 2020Date of Patent: November 22, 2022Assignee: AMGEN K-A, INC.Inventors: Dingjiang Liu, Holly Zhuohong Huang, David Andrew Martin, Christopher Boyd Russell, David H. Salinger, Scott Walter Baumgartner, Christopher Endres
-
Patent number: 11492396Abstract: The invention relates to therapeutic uses of antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F in the treatment of dermatological and rheumatological diseases, such as psoriasis, psoriatic arthritis and axial spondyloarthritis.Type: GrantFiled: October 26, 2016Date of Patent: November 8, 2022Assignee: UCB BIOPHARMA SRLInventors: Sophie Glatt, Lucian Ionescu, Margaret Jones, Ruth Oliver, Stevan Graham Shaw, Foteini Strimenopoulou, Venkata Pavan Kumar Vajjah
-
Patent number: 11447574Abstract: The monoclonal IgG-type antibodies were suggested comprising variable domains represented by a combination of VHH-derivative with a variable domain of the light chain VL. Said antibodies can comprise amino acid substitutions at positions 44 and 45 (Kabat numbering) or combinations thereof. Antibodies of the invention possess increased affinity and improved aggregation stability.Type: GrantFiled: September 9, 2019Date of Patent: September 20, 2022Inventors: Andrey Borisovich Ulitin, Stanislav Rudolfovich Evdokimov, Valeriy Vladimirovich Soloviev, Yulia Sergeevna Chernykh, Olga Vladimirovna Goncharova, Dmitriy Valerievich Korzhavin, Tatyana Veniaminovna Chernovskaya, Timofey Aleksandrovich Nemankin, Roman Alexeevich Ivanov, Dmitriy Valentinovich Morozov, Victoria Mikhailovna Ekimova, Ekaterina Vladimirovna Sofronova, Yakov Yurevich Ustyugov
-
Patent number: 11434276Abstract: Provided are compositions for increasing the half-life of a polypeptide or polypeptides in a canine and methods of their use. The compositions involve variant canine IgG Fc regions.Type: GrantFiled: May 11, 2021Date of Patent: September 6, 2022Assignee: Invetx, Inc.Inventors: William Brondyk, Brett Chevalier, Juergen Horn, Madhusudan Natarajan
-
Patent number: 11434286Abstract: Uses of IL-13 antagonists for treating atopic dermatitis are provided. Also provided are methods of treating atopic dermatitis and methods of reducing the severity of atopic dermatitis by administering IL-13 antagonists.Type: GrantFiled: March 18, 2019Date of Patent: September 6, 2022Assignee: Genentech Inc.Inventors: ChinYu Lin, Theodore A. Omachi, Ryan P. Owen, Karl Yen, Yanan Zheng, Kendra Debusk
-
Patent number: 11421025Abstract: The present invention provides a vaccine against IL-17A, which uses, as an immunogen, a polypeptide containing the amino acid sequence shown in SEQ ID NO: 1, or an amino acid sequence derived from a non-human mammal, which corresponds to SEQ ID NO: 1, a prophylactic or therapeutic agent containing the vaccine for diseases involving IL-17A as an aggravation factor, and the like.Type: GrantFiled: December 26, 2014Date of Patent: August 23, 2022Assignee: OSAKA UNIVERSITYInventors: Hiroshi Koriyama, Hironori Nakagami, Ryuichi Morishita
-
Patent number: 11407824Abstract: The present invention relates to anti-IL-1 beta antibodies and in particular to monovalent high potency IL-1 beta-binding antibody fragments being highly stable. Such antibodies can be used in the treatment of inflammatory and other diseases as well as in diagnostics. Also provided are related nucleic acids, vectors, cells, and compositions.Type: GrantFiled: February 6, 2020Date of Patent: August 9, 2022Assignee: Cell Medica, Inc.Inventors: Annemarie Honegger, Titus Kretzschmar, Simone Schmitt, Abdijapar Shamshiev, Stefanie Grabulovski
-
Patent number: 11396541Abstract: The present disclosure provides antibodies and antibody fragments thereof that bind to IL-23p19. The disclosed antibodies and antibody fragments thereof can modulate a biological activity of the IL-23 receptor signaling axis and are therefore useful for the treatment of immune-mediated inflammatory disorders.Type: GrantFiled: November 13, 2020Date of Patent: July 26, 2022Assignee: NOVAROCK BIOTHERAPEUTICS, LTD.Inventors: Haichun Huang, Ming Lei, Yi Pei, Han Li
-
Patent number: 11358998Abstract: The present invention refers to a secretion-competent mutein of the ?-subunit of human Interleukin 27 and to a human heterodimeric Interleukin 27. The present invention further refers to a nucleic acid molecule comprising a nucleotide sequence encoding a secretion-competent mutein of the ?-subunit of human Interleukin 27 or the human heterodimeric Interleukin 27, to a host cell containing a nucleic acid molecule comprising a nucleotide sequence encoding a secretion-competent mutein of the ?-subunit of human Interleukin 27 or of the human heterodimeric Interleukin 27. The invention also refers to an immune modulator comprising a secretion-competent mutein of the ?-subunit of human Interleukin 27 or of the human heterodimeric Interleukin 27, to the respective use thereof as well as to a method of producing said secretion-competent muteins and to a secretion-incompetent mutein of the ?-subunit of mouse Interleukin 27 and a secretion-competent mutein of the ?-subunit of mouse Interleukin 27.Type: GrantFiled: May 4, 2018Date of Patent: June 14, 2022Assignee: TECHNISCHE UNIVERSITAET MUENCHENInventors: Matthias Feige, Stephanie Mueller
-
Patent number: 11351253Abstract: The disclosure is directed to methods, treatment regimens, uses, kits and therapies for treating Generalized Pustular Psoriasis (GPP). These methods, treatment regimens, uses, kits and therapies utilize, inter cilia, administration of an IL-17 antagonist, e.g., an IL-17 antibody, such as secukinumab. Additionally disclosed are improved methods for treating plaque-type psoriasis that utilize up-titration and down-titration of the IL-17 antagonist, e.g., an IL-17 antibody, such as secukinumab, as well as modification of dose frequency. Further disclosed are methods of treating palmoplantar pustular psoriasis using the disclosed IL-17 antagonists, e.g., IL-17 antibodies, such as secukinumab.Type: GrantFiled: August 29, 2019Date of Patent: June 7, 2022Assignee: NOVARTIS AGInventors: Charis Papavassilis, Oliver Sander, Tomohiro Shima, Susumu Kitamura
-
Patent number: 11346849Abstract: An in-vitro method for the prediction, prognosis and/or diagnosis of an inflammatory response associated with a condition or disease such as schizophrenia in a subject, the method comprising determining in a sample of a subject the level of 25-hydroxy vitamin D3, preferably in combination with the level of least one biomarker wherein the at least one biomarker is selected from innate chemokine (IL-8) and matrix metalloproteinase (MMP-9); and comparing the levels of said 25-hydroxy vitamin D3 and at least one biomarker to a control level of 25-hydroxy vitamin D3 and the at least one biomarker respectively in order to determine a positive or negative prediction, prognosis and/or diagnosis of said inflammatory response indicating an associated condition or disease, such as schizophrenia.Type: GrantFiled: June 17, 2014Date of Patent: May 31, 2022Inventor: Ute-Christiane Meier
-
Patent number: 11332507Abstract: The invention relates to IL-22 polypeptides, IL-22 Fc fusion proteins and IL-22 agonists, composition comprising the same, methods of making and methods of using the composition for the treatment of diseases. The invention also relates to IL-22 receptor associated reagents and methods of use thereof.Type: GrantFiled: September 11, 2018Date of Patent: May 17, 2022Assignee: Genentech, Inc.Inventors: Justin Scheer, Wenjun Ouyang, Richard Vandlen, Philip E. Hass, Eric Gary Stefanich, Xiaoting Wang
-
Patent number: 11292833Abstract: The present disclosure relates to methods for selectively reducing CysL97 in a preparation of IL-17 antibodies or antigen binding fragments thereof (e.g., a preparation of secukinumab antibodies) that have been recombinantly produced by mammalian cells. Also provided are purified preparations of IL-17 antibodies or antigen binding fragments thereof produced by such methods, e.g, purified preparations of secukinumab, wherein the level of intact IL-17 antibodies or antigen binding fragments thereof (e.g., secukinumab) in the preparation is high, e.g., at least about 90%, as measured by sodium dodecyl sulfate capillary electrophoresis (CE-SDS), and wherein the level of activity of IL-17 antibodies or antigen binding fragments thereof (e.g., secukinumab) in the preparation is high, e.g., at least about 92%, as measured by cation exchange chromatograph (CEX).Type: GrantFiled: December 21, 2015Date of Patent: April 5, 2022Assignee: NOVARTIS AGInventors: Markus Heitzmann, Johann Winkler
-
Patent number: 11279755Abstract: Methods for treating eye diseases such as dry eye disease (DED) and age-related macular degeneration (AMD) using an IL-20 antagonist that blocks the signaling pathway mediated by IL-20, for example, an antibody that binds IL-20 or an IL-20 receptor.Type: GrantFiled: April 25, 2018Date of Patent: March 22, 2022Assignee: LBL Biotechnology, Inc.Inventor: Ming-Shi Chang